Compare Nasdaq Inc (NDAQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs BIO-TECHNE Corp — how do they compare? Nasdaq Inc trades at $95.02 (market cap $53.45B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Nasdaq Inc is far larger — about 4.8× BIO-TECHNE Corp's market cap, and Nasdaq Inc pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| NDAQ | TECH | |
|---|---|---|
Market Cap | $53.45B | $11.24B |
Sector | Financials | Health |
52-Week High | $100.98 | $72.29 |
52-Week Low | $76.85 | $43.31 |
Enterprise Value | $59.91B | $11.32B |
Dividend Yield | 1.21% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $94.59, down slightly by 0.12% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.07 per share, beating estimates, and maintains robust profitability with a 22.52% net income margin. Recent news highlights steady exchange operations and strategic growth initiatives.
Outlook remains positive with a consensus price target of $109.20, implying 15% upside. Risks include market volatility and competitive pressures, but solid fundamentals and analyst buy ratings support a favorable investment case for long-term growth.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
